BOSTON, Sept. 15, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company is participating in upcoming events to discuss challenges and opportunities in ultra-rare disease drug development.
Read more at prnewswire.comStealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events
PR Newswire - Press Release 
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Microsoft%20Corporation%20logo%20on%20sign-by%20Jean-Luc%20Ichard%20via%20iStock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/Alphabet%20Inc_%20and%20Google%20logos%20seen%20displayed%20on%20a%20smartphone%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
/Phone%20and%20computer%20internet%20network%20by%20Pinkypills%20via%20iStock.jpg)
/NVIDIA%20Corp%20logo%20on%20phone-by%20Evolf%20via%20Shutterstock.jpg)